These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30461207)

  • 61. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia.
    Haddad P; Karimi M
    Radiother Oncol; 2002 Jul; 64(1):29-32. PubMed ID: 12208571
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
    Sasse AD; Clark LG; Sasse EC; Clark OA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas.
    Ghosh Laskar S; Sinha S; Kumar A; Samanta A; Mohanty S; Kale S; Khan F; Lewis Salins S; Murthy V
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):353-361. PubMed ID: 38575432
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
    Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
    Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects.
    Sagowski C; Wenzel S; Metternich FU; Kehrl W
    Eur Arch Otorhinolaryngol; 2003 Jan; 260(1):42-7. PubMed ID: 12520356
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial.
    Athanassiou H; Antonadou D; Coliarakis N; Kouveli A; Synodinou M; Paraskevaidis M; Sarris G; Georgakopoulos GR; Panousaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1154-60. PubMed ID: 12829154
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial.
    Cohen L; Danhauer SC; Garcia MK; Dressler EV; Rosenthal DI; Chambers MS; Cusimano A; Brown WM; Ochoa JM; Yang P; Chiang JS; Gordon O; Crutcher R; Kim JK; Russin MP; Lukenbill J; Porosnicu M; Yost KJ; Weaver KE; Lesser GJ
    JAMA Netw Open; 2024 May; 7(5):e2410421. PubMed ID: 38739392
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
    Haddad R; Wirth L; Costello R; Weeks L; Posner M
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):84-8. PubMed ID: 14727246
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
    Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M
    J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized Trial of Vitamin C/E Complex for Prevention of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer.
    Chung MK; Kim do H; Ahn YC; Choi JY; Kim EH; Son YI
    Otolaryngol Head Neck Surg; 2016 Sep; 155(3):423-30. PubMed ID: 27048670
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
    Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
    Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
    Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
    Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients.
    Saavedra MM; Henríquez-Hernández LA; Lara PC; Pinar B; Rodríguez-Gallego C; Lloret M
    J Radiat Res; 2010; 51(5):603-7. PubMed ID: 20699603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.
    Sangthawan D; Watthanaarpornchai S; Phungrassami T
    J Med Assoc Thai; 2001 Feb; 84(2):195-203. PubMed ID: 11336078
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of xerostomia related to radiotherapy for head and neck cancer.
    Kahn ST; Johnstone PA
    Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer.
    Warde P; O'Sullivan B; Aslanidis J; Kroll B; Lockwood G; Waldron J; Payne D; Bayley A; Ringash J; Kim J; Liu FF; Maxymiw W; Sprague S; Cummings BJ
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):9-13. PubMed ID: 12182969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.